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Abstract  Background Glomerular endothelium dysfunction plays crucial roles in the 
pathogenesis of early diabetic nephropathy (DN) and might be caused by circulating 
metabolic abnormalities. Platelet microparticles (PMPs) are extracellular vesicles 
released from activated platelets and have recently emerged as a novel regulator of 
vascular dysfunction. This study aimed to investigate the effects of PMPs on glomerular 
endothelial injury in early DN. Methods Streptozotocin-induced diabetic rat model and 
primary rat glomerular endothelial cells (GEnCs) were used for experiments. Isolated 
PMPs were measured by flow cytometry. Results Plasma PMPs were significantly 
increased in diabetic rats, which was inhibited by aspirin. In cultured GEnCs, PMPs 
induced the production of reactive oxygen, decreased nitric oxide level, inhibited the 
activities of endothelial nitric oxide synthase and superoxide dismutase, decreased the 
barrier permeability of the GEnCs, and reduced the thickness of endothelial surface 
layer. Conversely, inhibition of PMPs in vivo by aspirin improved glomerular 
endothelial injury. Further analysis showed that PMPs activated the mammalian target 
of rapamycin complex 1 (mTORC1) pathway in GEnCs and inhibition of the mTORC1 
pathway by rapamycin or raptor siRNA significantly protected against PMPs-induced 
glomerular endothelial injury	 in vivo and in vitro. Moreover, PMPs contributed to 
glomerular endothelial injury induced by PMP-derived chemokine (C-X-C motif) 
ligand 7 (CXCL7), and antagonizing CXCL7 using CXCL7 neutralizing antibody or 
blocking CXCL7 receptor by SB225002 dramatically attenuated PMPs-induced 
glomerular endothelial injury. Conclusions These findings demonstrate a pathogenic 
role of PMPs in glomerular endothelium dysfunction, which might be a potential 




Diabetic nephropathy (DN) is one of the most common microvascular complications of 
diabetes.1 Despite increasing research progress in the treatment of DN, the incidence 
and prevalence of end-stage renal disease (ESRD) are rapidly rising worldwide.2-4 
The glomerular endothelium is the first layer of the glomerular filtration barrier (GFB), 
consisting of glomerular endothelial cells (GEnCs), the endothelial surface layer (ESL) 
and fenestrations, and tight junctions among cells.5 GEnCs are highly specialized cells 
characterized by the presence of 60-80 nm transcellular fenestrations and covered with 
ESL.6, 7 Glycocalyx is the main component of the ESL, which covers both fenestral and 
inter-fenestral domains of the GEnC luminal surface.5-7 The fenestrations and covered 
glycocalyx with characteristics of the molecular and charge barrier are essential for 
selective permeability.7, 8 The glomerular endothelium is encountered by plasma and 
forms the first barrier to macromolecular substances. In addition, the glomerular 
endothelium makes an important contribution to maintaining the homeostasis within 
the glomerulus in response to haemodynamic changes by secreting vasoactive 
substances. It is increasingly recognized that glomerular endothelial dysfunction is an 
early and deleterious hallmark of DN, resulting in impairment of the GFB and the 
appearance of albuminuria.7, 9, 10 The thickness of the glycocalyx and mean percentage 
of fenestrations in glomerular endothelium were reduced in DN, which was correlated 
tightly with the permeability of the GFB and albuminuria.11, 12 Improvement of 
glomerular glycocalyx by inhibiting the heparanase level reduced glomerular 
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permselectivity and the development of albuminuria.13 Recent studies have shown that 
endothelial nitric oxide synthase (eNOS) knockout mice develop aggravated DN with 
extensive mesangial expansion and severe podocyte injury, suggesting a causal link 
between endothelial dysfunction and the onset of early DN.14, 15 However, the initiating 
factors and related mechanisms of glomerular endothelial injury in early DN are still 
unclear. 
Platelet microparticles (PMPs) are extracellular vesicles (EVs) derived from activated 
platelets that range in size from 0.1 to 1 µm in diameter.16-18 PMPs account for 70%–
90% of all the circulating microparticles.16 PMPs enriched in proteins, lipids, and 
genetic information derived from activated platelets have the ability to modify the 
phenotype and function of the target cells.19-21 PMPs increase the expression of 
intercellular adhesion molecule-1 (ICAM-1) in endothelial cells by delivering 
arachidonic acid and inflammatory cytokines, leading to monocyte adherence to the 
vessel wall.22 In the condition of diabetes, the levels of circulating MPs are highly 
elevated, strongly associated with the urinary albumin excretion rate.23-26 However, 
whether PMPs contribute to glomerular endothelium dysfunction in early DN is still 
unknown. 
Therefore, this study aimed to investigate the role of PMPs in glomerular endothelial 





Male Sprague-Dawley (SD) rats weighing 200-220 g were obtained from Shanghai 
Bikai Company (China). The rats were maintained under a constant 12-hour 
photoperiod at temperatures ranging from 21-23°C and allowed free access to food and 
water, acclimatized for at least a week before further operation. All protocols, including 
diabetes induction and sacrifice operation, were approved by the Institutional Animal 
Care and Use Committee of Southeast University. 
Diabetes was induced by streptozotocin (STZ) injection as described previously.27 
Briefly, rats were injected with 60 mg/kg body weight of STZ (Sigma, USA) once 
intraperitoneally. After 72 hours of STZ injection, blood glucose levels were measured, 
and rats with a blood glucose level higher than 16.7 mmol/l were diagnosed as diabetic 
rats. For the normal controls, rats were injected with 0.1 mol/l sodium citrate buffer 
once intraperitoneally. At week 3 after diabetes induction, the rats were divided into 
four groups (n=10): normal controls treated with vehicle (Ctrl), diabetic rats treated 
with vehicle (DM), diabetic rats treated with aspirin (15 mg/kg) (DM+Asp), and 
diabetic rats treated with rapamycin (1 mg/kg) (DM+Rapa). Aspirin was given by 
intragastric administration daily in the whole study period. Body weight and 24-hour 
urine volume were determined weekly until being killed at the week 4, 8, and 12. The 
concentrations of blood urea nitrogen (BUN) and serum creatinine were determined 
using automatic analysers (Hitachi, Japan). Urinary albumin levels were measured 
using an enzyme-linked immunosorbent assay. 
6	
	
GEnC isolation, culture, and identification 
Glomeruli were isolated from rat kidneys under sterile conditions by differential sieving 
as previously described.28 Briefly, male SD rats (150-200 g) were anaesthetized by an 
intraperitoneal injection of chloral hydrate (400 mg/kg). Kidneys were isolated and 
placed into cold sterile Hank's solution. After tearing the renal capsule from the lavaged 
kidney, the renal cortex was cut into 1-2-mm3-thick fragments. The kidney tissues were 
ground with a 100-mesh stainless steel sieve, followed by filtering through 150 and 
200-mesh steel sieves, respectively. Glomeruli in the 200-mesh steel sieve were 
collected and centrifuged at 460 g for 5 minutes. After two washes with serum-free 
Dulbecco's Modified Eagle’s Medium (DMEM), the glomeruli were treated with type 
IV collagenase (1 g/L) for 30 minutes at 37°C and then centrifuged at 460 g for 5 
minutes. The supernatant was eliminated, and the pellet was washed twice with serum-
free DMEM to collect the glomeruli. The glomeruli were seeded in a culture flask pre-
coated with 10 µg/ml collagenⅠand the prepared endothelial cell medium. The 
endothelial cell medium was replaced every 3 days, and the GEnCs were grown in a 
confluent monolayer during the second week. Identification of GEnCs was made using 
immunofluorescent staining (Supplemental Figure 3). 
For the mTORC1 pathway inhibition, GEnCs were treated with 10 ng/ml Rapamycin 
(Sigma, USA) or transfected with raptor siRNA using Lipofectamine 2000 (Invitrogen, 
USA) per the recommendations of the manufacturer. 
The isolation of circulating microparticles 
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Circulating microparticles (MPs) were separated according to the method reported by 
Dasgupta et al.29 Briefly, circulating MPs were isolated by differential centrifugation. 
Blood was sampled by right heart puncture using 10 ml syringe and then added to 
polypropylene tubes with 0.129 mol/l sodium citrate. Platelet-rich plasma (PRP) was 
obtained by centrifugation at 1000 g for 15 minutes at 18°C. The PRP was then 
centrifuged at 5000 g for 15 minutes at 18°C to obtain platelet-free plasma (PFP). The 
PFP was further centrifuged using an Eppendorf 5424R centrifuge machine at 20000 g 
for 30 minutes to precipitate MPs at 18°C. The pellets containing MPs were suspended 
in modified Tyrode’s buffer(MTB) and stored at -80°C.  
Measurement of circulating PMPs  
To label PMPs, resuspension solution containing MPs was incubated with 
allophycocyanin (APC)-labelled Annexin V (Vazyme Biotech, China) and 
phycoerythrin (PE)-conjugated CD61 antibody (BD Biosciences, USA) for 30 minutes. 
As a negative control, a subpopulation of MPs was resuspended in Annexin V binding 
buffer lacking calcium and containing a PE-conjugated IgG control antibody. The MPs 
were then centrifuged at 20000 g for 30 minutes to remove excess fluorescent dye and 
washed twice by centrifugation for 30 minutes at 20 000 g. The pellet resuspended in 
300 µl phosphate-buffered saline (PBS), followed the addition of 1×106 beads with a 
diameter of 3 µm. A tube containing beads with a diameter of 0.8 µm was used to gate 
the MPs. Finally, circulating PMPs were calculated by flow cytometry. 
PMP isolation from activated platelets in vitro 
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Blood was collected from rats into centrifuge tubes with acid citrate dextrose (ACD) 
buffer. After resting for 10 minutes at room temperature, the blood was centrifuged at 
282 g for 10 minutes at 22°C. The PRP was then centrifuged for 5 minutes at 400 g, 
and the supernatant was harvested and further centrifuged for 5 minutes at 1600 g to 
collect the platelets. After one wash of the pellet with citrate glucose saline (CGS) 
buffer, the platelets were resuspended in MTB. Platelets were counted and adjusted to 
a density of 3×108 cells/ml, followed by stimulation with 30 mmol/l of high glucose, 
20 µg/ml of collagen(TypeⅠcollagen, Sigma), or high glucose plus collagen for 30 
minutes at 37°C. Ethylenediaminetetraacetic acid (20 mmol/l) was added to stop the 
platelet activation, and the residual platelets were removed by centrifuging twice for 5 
minutes each at 2000 g. The supernatant was harvested and centrifuged for 90 minutes 
at 20000 g and 18°C to collect PMPs. Finally, the pellet containing the PMPs was 
resuspended in MTB. PMPs were stored at -80°C. To remove background dust and 
crystals, all reagents were double-filtered with 0.22-µm filters. 
Protein microarray assay 
Cytokines and chemokines in PMPs derived from platelets that were untreated or 
treated with collagen plus high glucose were measured using the Proteome ProfilerTM 
(R&D, USA) according to the manufacturer’s recommendations. 
Histology and immunofluorescent staining 
For histological analysis, tissues were dissected and fixed in 4% paraformaldehyde and 
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then embedded in paraffin. Sections were stained with periodic acid–Schiff (PAS) after 
deparaffinization. To evaluate the glomerular ESL glycocalyx, sections were stained 
with rhodamine-labelled wheat germ agglutinin (WGA) lectin (10 µg/ml) for 2 hours 
at room temperature after deparaffinization and analysed by Olympus fluorescence 
microscopy. For immunofluorescence, GEnCs and kidney sections were fixed with 4% 
paraformaldehyde for 30 minutes and treated with 0.05% Triton X-100 for 10 minutes. 
After blocking with 5% BSA, samples were stained with antibodies against CD61 
(Novusbio, USA), CD63（Abcam, USA）, glypican-1, syndecan-1, CD31 (Santa Cruz, 
USA), and p-S6K1 (Abcam, USA). Secondary antibodies conjugated to Alexa Fluor 
488, 555 or 594 were used (Life Technologies, USA). Nuclei were labelled with 4’,6-
diamidino-2-phenylindole. Coverslips were mounted on slides with glycerine and 
analysed by Olympus fluorescence microscopy. Fluorescent intensity analysis was 
performed with Image J. 
PMPs internalization assay  
Purified PMPs were labelled with PE-CD61 and incubated with GEnCs for 2, 4 or 12 
hours. For uptake inhibition experiments, GEnCs were co-incubated with different 
inhibitors, as described in Figure. 2. Cells were fixed, permeabilized, and stained for 
CD31 with Alexa-Fluor-488 (Invitrogen，USA) and with the nuclear dye 4', 6-
diamidino-2-phenylindole (DAPI). Imaging was performed on a fluorescence 
microscopy (Olympus, Japan) and fluorescent intensity analysis was performed with 
Image J.  
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The ultra-microstructure observation of PMPs 
Rat kidneys were dissected and fixed in a mixture of 4% paraformaldehyde and 2.5% 
glutaraldehyde fixative buffered with PBS. After post-fixation with 0.4% OsO4, the 
samples were dehydrated with a graded series of acetone before embedding in Epon 
812. After stained with uranyl acetate and lead citrate, the sections were observed with 
a JEM1230. The morphology of the isolated PMPs was determined using electron 
microscopy. PMPs pellets were fixed in 4% paraformaldehyde for 30 minutes. The 
pellets were then loaded on grids coated with formvar carbon and stained with 0.75% 
uranyl acetate. Sections were observed with a Philips Tecnai-10 transmission electron 
microscopy operating at 80 kilovolts (Phillips Electronic Instruments, USA). We 
further checked PMPs deposition in glomerular endothelial cells by immunoelectron 
microscopy assay. Brifely, 70 nm kidney sample sections were transferred to formvar-
carbon coated copper grids.	1%H2O2 etching was used to remove osmium acid and then 
blocked with 5%BSA at room temperature for 60 minutes.The samples were then 
incubated with anti-CD61 antibody followed by secondary antibody conjugated with 
10 nm gold.	Finally, sections were observed with a Philips Tecnai-10 transmission 
electron microscopy. 
Real-time polymerase chain reaction (PCR) 
Total RNAs of GEnCs were extracted using TRIzol referring to the the manufacturer’s 
instructions. The mRNA expression was detected by real-time PCR using the SYBR 
Green PCR Master Mix (Takara, Japan). The primer sequences are listed in 
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supplemental table 1. 
Western blot analysis 
Identical amounts of total protein extracts from renal cortex or cells were loaded and 
separated by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis, and the 
proteins were then transferred onto a nitrocellulose membrane. After treatment with 
blocking solution, the membranes were incubated with anti-rat antibodies against CD61, 
glypican-1, syndecan-1, ZO-1, occludin, CD31, mTOR, p-mTOR, S6K1, p-S6K1, 
4EBP1, and p-4EBP1 overnight at 4°C,	followed by horseradish peroxidase-conjugated 
secondary antibodies for two hours at 4℃. Finally, the results were determined using 
the ECL Advance system (Amersham Biosciences, USA). 
Determination of ROS, NO, SOD, and eNOS 
Cellular reactive oxygen species (ROS) were monitored as previously described. 30 
Briefly, GEnCs were incubated with 10 µmol/l fluorescent probe DCFH-DA at 37°C 
for 30 minutes. After washing with PBS, the cells were harvested and resuspended in 
DMEM for flow cytometry. The nitric oxide (NO) levels in the renal cortex and cellular 
supernatant were measured using a commercially available NO assay kit. Nitric oxide 
synthase (NOS) activity in GEnCs was measured by detecting the conversion of l-[14C] 
arginine to l-[14C] citrulline using a commercial NOS Detect Assay kit. The anti-
oxidative enzyme activity of superoxide dismutase (SOD) was measured using a 




GEnCs permeability assay 
The permeability assay of the GEnCs was performed as previously described.31 GEnCs 
were cultured in transwell plates. When cells in transwell membranes were fully 
confluent and formed an intact monolayer, the cells were treated for 24 hours. The cell 
culture medium was then removed, and 100 µl DMEM alone in the presence of 
fluorescein-isothiocyanate-labelled bovine serum albumin (FITC-BSA, 0.25 mg/ml) 
was added to the upper compartment. The medium of the lower compartment was 
collected after 60 minutes. FITC-BSA was quantified in a fluorescence 
spectrofluorophotometer. The BSA flux was valued as a ratio between fluorescence 
intensities in the lower compartment and the upper compartment. 
Statistical analysis  
Results are expressed as the mean±SD. Statistical analysis was performed using SPSS 
16.0. Statistical comparisons among multiple groups were analysed for significance by 
one-way analysis of variance (ANOVA) followed by Tukey’s or Games-Howell post 
hoc tests, or the Mann-Whitney U test for a nonparametric test. P<0.05 was considered 
a significant difference. 
Results 
Inhibition of PMPs decreased albuminuria and ameliorated glomerular 
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hypertrophy and mesangial matrix accumulation in early DN  
We first determined whether PMPs were increased in a STZ-induced DM rat model. 
Circulating total MPs were isolated and detected by electron microscopy and flow 
cytometry assays. As shown in Figure 1A-B, vesicles from plasma ranged in size from 
0.1 to 0.8 µm with clear intact double layer membrane structure. Using electron 
microscopy, we also found that DM rats produced more MPs than untreated controls. 
Treatment with aspirin significantly decreased MP formation at week 12(Figure 1B). 
To determine the plasma levels of PMPs, the specific marker CD61 of platelets with 
Annexin V were used to detect PMPs. Flow cytometry showed that the majority of these 
MPs were CD61 and Annexin V-positive PMPs, which gradually increased from week 
4 to week 12 in diabetic rats compared with the controls (Figure 1C-D). Furthermore, 
by the end of week 12, the mean PMP count in the plasma of diabetic rats reached 
20×106/ml (Figure 1D). Aspirin is one of the most commonly used anti-platelet agents 
and has potential effects on the prevention of platelet activation. The results showed 
that plasma levels of PMPs in diabetic rats treated with aspirin were significantly 
decreased starting from week 8 (Figure 1D). We further observed the PMPs infiltration 
in the glomeruli of rats. The results showed quantities of CD61-positive particles 
accumulated in the glomeruli of diabetic rats compared with the controls, suggesting 
that larger clusters of PMPs were deposited in the glomerulus (Figure 1E-F).	In order 
to distinguish platelets and PMPs, kidney sections were incubated with freshly isolated 
platelets and stained with anti-CD61 antibody. The results showed the complete platelet 
structure in glomerulus and the PMPs were much smaller than the intact platelets 
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resided around the nuclei (supplemental Figure 2A). Double immunofluorescent 
staining showed that CD63, a biomarker for extracellular vesicle, overlapped with 
CD61 (Figure 1G). The co-localization confirmed that the CD61-positive structures 
represent PMPs. To further confirm that PMPs were internalized by glomerular 
endothelial cells, we ultrastructurally observed the deposition of PMPs in glomerular 
endothelial cells by immunoelectron microscopy assay. Results showed that there were 
quantities of CD61 positive dark black particles deposited in the cells, suggesting that 
PMPs were uptaked by glomerular endothelial cells (Supplemental Figure 2B). 
Moreover, Western blotting further demonstrated that CD61 protein expression was 
markedly upregulated in the kidneys of diabetic rats at week 12 (Figure 1H-I), 
suggesting that PMPs were incorporated into the glomerulus during the progression of 
DN. Interestingly, the deposition of PMPs in diabetic kidney was reduced after aspirin 
treatment (Figure 1E-F). 
We then examined the role of the increased PMPs in the kidney injury of diabetic rats. 
Aspirin treatment did not affect the blood glucose levels of diabetic rats (Figure 1J). 
The results demonstrated no differences in serum creatinine in diabetic compared with 
control rats, although an increase in BUN was detected in diabetic rats from week 8 to 
week 12 (Figure 1K-L). Interestingly, inhibition of PMPs by aspirin was able to 
override the elevated urinary albumin/creatinine ratio (ACR) and	kidney body weight 
ratio in diabetic rats (Figure 1M-N). PAS staining indicated that glomerular hypertrophy 
and mesangial matrix expansion in early DN were markedly ameliorated by aspirin 
treatment (Figure 1O-Q). Furthermore, after aspirin treatment, decreased plasma PMP 
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levels in diabetic rats were positively associated with a significant reduction of ACR 
(Figure 1R). 
PMPs induced glomerular endothelial injury in early DN 
As the glomerular endothelium directly contacts circulating PMPs, we checked the 
effects of PMPs on glomerular endothelial injury. Immunofluorescent staining showed 
that with an extended time of PMP co-incubation with GEnCs, endothelial cells showed 
increased PMP uptake (Figure 2A).	 To test whether PMPs were internalized by 
endothelial cells, we labelled PMPs with a R-phycoerythrin (PE)-tagged CD61 and co-
incubated with GEnCs. High magnification pictures and the Z-section analysis 
indicated that most of the labelled PMPs were uptaken by GEnCs, and a few of them 
were combined on the membrane (Figure 2B,	Supplemental Figure 7).	To test whether 
uptake of PMPs into GEnCs was through endocytic pathways, we co-incubated GEnCs 
with PMPs alone or together with a series of known endocytosis inhibitors.	Dynasore 
is an inhibitor of dynamin-2 required both for clathrin-mediated and caveolin-
dependent endocytosis. Chlorpromazine, an inhibitor of clathrin-mediated endocytosis. 
We tested dynasore, chlorpromazine, the actin filament inhibitors - latrunculin A and 
cytochalasin D, and the microtubule inhibitors - nocodazole. We found that all these 
inhibitors had significant effects on PMPs uptake (Figure 2C-D), strongly suggesting 
that PMPs internalization by GEnCs is indeed via endocytosis.  
The PMPs isolated from the plasma of diabetic rats decreased NO production and 
increased ROS levels in GEnCs in a dose-dependent manner (Figure 2E-F), indicating 
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that the PMPs from diabetic rats induced GEnCs dysfunction. To further confirm the 
effects of PMPs on endothelial injury, we isolated PMPs in vitro from cultured rat 
platelets activated with different agonists. The results demonstrated that the generation 
of PMPs from activated platelets stimulated by high glucose plus collagen (Col+HG-
PMPs) was remarkably increased compared with high glucose (HG-PMPs) or collagen 
alone (Col-PMPs) (Figure 2G), suggesting that a high glucose background is a critical 
factor inducing and amplifying PMP generation in diabetes. A significant reduction of 
the NO levels was observed, with inhibition of eNOS and SOD activities, in contrast to 
increased production of ROS in GEnCs during stimulation with Col+HG-PMPs (Figure 
2H-K). Consistently, immunofluorescence analysis confirmed that Col+HG-PMPs 
reduced the expression of glycocalyx-associated core proteins glypican-1 and 
syndecan-1 (Figure 2L). In addition, GEnC permeability was enhanced by Col+HG-
PMPs, as shown by a significant increase in trans-endothelial FITC-BSA flux (Figure 
2M).  
The in vivo results revealed a gradually reduction of the ESL thickness, as assessed by 
rhodamine-WGA staining in diabetic rats compared with controls, which were reversed 
by aspirin (Figure 3A-B). Immunofluorescence and Western blot assays also revealed 
that expression levels of the glycocalyx-associated core proteins glypican-1 and 
syndecan-1 as well as the tight junction-associated protein ZO-1 and occludin in 
glomerular endothelium were downregulated in diabetic rats, whereas aspirin provided 
a protective role for the GEnC glycocalyx and tight junction in early DN (Figure 3C-
H). Moreover, inhibition of PMPs by aspirin caused a reduction of ET-1 expression and 
17	
	
improvement of GEnC fenestration in diabetic rats (Figure 3G-K). To observe the effect 
of PMPs on GEnCs diastolic function, we detected the NO level and SOD activity in 
the kidney cortex. As shown in Figure 3L-M, the NO level and SOD activity were 
decreased in diabetic rats; however, this response was mitigated by aspirin treatment.  
PMPs activated the mTORC1 pathway in GEnCs 
We next investigated potential mechanisms of PMP-induced glomerular endothelial 
injury. The mTORC1 is a rapamycin-sensitive protein kinase complex that regulates 
processes of cell growth, metabolism, proliferation, and autophagy by phosphorylating 
p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4EBP1). 
Hyperactivation of mTORC1 in kidney cells is associated with early changes in DN. 
Although we did not observe a significant difference in mTOR, S6K1 and 4EBP1 at the 
mRNA level between the control and PMP-stimulated group (Figure 4A-C), 
immunofluorescent staining and Western blot analysis showed that PMPs significantly 
increased protein phosphorylation of mTOR, S6K1, and 4EBP1, indicating a 
hyperactivation of the mTORC1 pathway (Figure 4D-F). In the in vivo study, double 
immunofluorescent staining of p-S6K1 and CD31 showed that S6K1 phosphorylation 
was increased in the cytoplasm of CD31-positive cells in diabetic rats, suggesting an 
upregulation of mTORC1 activity in the glomerular endothelium(Figure 4G). Aspirin 
treatment prevented S6K1 phosphorylation in glomerular endothelial cells of diabetic 
rats (Figure 4G). Consistent with these findings, Western blot analysis also showed 
higher levels of p-mTOR, p-S6K1 and p-4EBP1 in the glomeruli of diabetic rats, which 
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were reversed by aspirin, confirming the contribution of PMPs to mTORC1 activation 
(Figure 4H-I).  
PMPs mediated glomerular endothelial injury through activation of the mTORC1 
pathway 
To confirm whether mTORC1 signalling is involved in PMP-mediated glomerular 
endothelial injury, rapamycin or raptor siRNA was used to block this pathway. Western 
blotting showed that the increased protein expression of p-mTOR, p-S6K1 and p-
4EBP1 in GEnCs was significantly inhibited by rapamycin or raptor-specific siRNA 
treatment (Figure 5A-B). Under these conditions, inhibition of mTORC1 reversed the 
PMP-induced decrease in NO levels and eNOS activity, and decreased ROS production 
(Figure 5C-E). Immunofluorescence and Western blot analysis indicated that rapamycin 
or raptor siRNA prevented PMP-induced upregulation of the ET-1 expression and 
downregulation of glypican-1, syndecan-1, ZO-1, and occludin (Figure 5F-H). 
Furthermore, inhibition of mTORC1 reversed the increased permeability of the 
glomerular endothelial cell barrier induced by PMP treatment (Figure 5I). To evaluate 
the role of mTORC1 signalling in glomerular endothelial injury of early DN, we treated 
diabetic rats with rapamycin. PMP deposition in the kidneys was not altered in 
rapamycin-treated compared with vehicle-treated diabetic rats (Figure 6A-B). As 
shown in Figure 6C-H, rapamycin prevented glomerular endothelial injury by 
improving the glomerular EC fenestration, ESL glycocalyx, and tight junctions, as well 
as by decreasing ET-1 expression. Moreover, rapamycin enhanced NO production and 
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SOD activity in the diabetic rats (Figure 6I-J).  
PMP-derived CXCL7 promoted GEnCs damage 
PMPs contain various pro-inflammatory and anti-inflammatory cytokines and 
chemokines deriving from platelets. PMPs can act as messengers and deliver these 
signals through soluble mediators, regulating lymphocyte rolling and activating 
endothelial cells, leukocytes and other platelets. Given the efficient uptake of PMPs by 
GEnCs (Figure 2B), we considered whether the binding of PMPs to GEnCs could 
deliver cytokines that target the mTORC1 signalling pathway. To characterize PMP-
derived cytokines, PMP lysates were analysed with cytokine protein microarrays. We 
surveyed a range of cytokines elicited from activated PMPs and observed a large 
amount of the chemokine CXCL7 (Supplemental Figure 8A-B). For the following 
experiments, we focused on CXCL7 because this is the most abundant cytokine in 
PMPs. Consistently, CXCL7 expression was significantly higher in activated PMPs 
than normal PMPs by ELISA analysis (Figure 7A). Because CXCL7 mediates its effect 
through the G-protein-coupled receptors CXCR1 and CXCR2, we analysed the 
expression of CXCR1 and CXCR2 in PMPs treated GEnCs by RT-PCR. The results 
revealed higher expression of CXCR1 and CXCR2 in GEnCs that received activated 
PMPs treatment compared with those treated with normal PMPs (Figure 7B). Next, we 
sought to determine whether the abundant CXCL7 could recapitulate the effect on the 
GEnCs mTORC1 pathway of PMPs. Western blot analysis showed that CXCL7 
increased the phosphorylation of mTORC1, S6K1 and 4EBP1 in GEnCs in a dose-
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dependent manner (Figure 7C-D). However, SB225002, a competitive inhibitor of 
CXCR1 and CXCR2, reduced the PMP-induced mTORC1 activation in GEnCs (Figure 
7E-F), indicating that CXCL7 is responsible for mTORC1 activation induced by PMPs 
in GEnCs. 
To ascertain that CXCL7 mediated PMPs induced GEnCs damage, CXCR1/2 in GEnCs 
was antagonized by SB225002, and diastolic function, glycocalyx, cell junctions and 
permeability were analysed in GEnCs. We found that pretreatment with the SB225002 
reversed the reduction of the NO level, eNOS and SOD activity, and decreased ROS 
production in GEnCs induced by PMPs (Figure 7G-J). Consistently, the destruction of 
the GEnC glycocalyx and cell junctions by PMPs was reversed by SB225002 (Figure 
7K-N). Furthermore, blockade of CXCL7 by SB225002 preserved the permeability of 
the GEnCs barrier disrupted by PMPs (Figure 7O). Moreover, to test whether the PMPs-
induced glomerular endothelial injury was dependent on CXCL7, CXCL7 blockade 
using CXCL7 neutralizing antibody was performed. Interestingly, anti-CXCL7 
treatment led to a marked reduction of mTORC1 activity, increase of glycocalyx, and 
recovery of glomerular endothelium function under the stimulation of PMPs (Figure 8). 
These results indicated that CXCL7/CXCR1/2 pathway played a crucial role in the 
PMPs-induced glomerular endothelial injury. 
Discussion  
The release of PMPs after platelet activation is considered to be a novel effector that 
may play a key role in the development of diabetic nephropathy. Here we report 
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PMPs participate in the intercellular communication between platelets and GEnCs via 
the delivery of platelet cytokines and regulation of protein expression, leading to 
glomerular endothelial injury and progression of early DN. 
Our data showed that plasma PMPs level was significantly elevated in STZ-induced 
diabetic rats from week 4, and approximately 80% of circulating MPs were derived 
from platelets. This result was further confirmed in an in vitro study showing that high 
glucose effectively enhanced the ability of platelets to generate PMPs in the presence 
of agonists, suggesting that high glucose is a crucial contributor to the rise in PMP 
levels in diabetes. By immunofluorescence and Western blot analyses, we observed a 
large amount of accumulated PMPs in the glomeruli of diabetic rats, but rarely in the 
glomeruli of normal rats. This difference likely reflected alterations in the quantity and 
function of PMPs, and the abnormal glomerular endothelial activation in diabetes, 
favouring the aggregation of PMPs. Importantly, the significant increase in the PMP 
level in plasma and the glomerulus was inhibited by aspirin treatment, indicating that 
aspirin is a potential PMP inhibitor in diabetes. Furthermore, inhibition of PMPs by 
aspirin significantly ameliorated DN by reducing albuminuria, glomerular hypertrophy 
and mesangial matrix expansion, and it had no effect on blood glucose level. These 
results suggested a strong association between the increased PMP level and the 
progression of early DN.  
Considering that the glomerular endothelium is in direct contact with blood and is 
vulnerable to PMPs, we then studied the effect of PMPs on the glomerular endothelium. 
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First, we demonstrated that most of plasma-derived PMPs from diabetic rats were 
uptaken by GEnCs when co-incubated in vitro and then PMPs were internalized by 
GEnCs via endocytosis in a variety of forms. The role of PMPs in diseases has recently 
begun to emerge and varies with different disease conditions and the different types of 
cells.29, 32, 33 PMP stimulation in vitro induced tumour cell apoptosis,34 inhibited 
regulatory T cell production of IL-17,35 and induced fibroblast-like synoviocytes to 
release IL-8.36 Our results indicated that plasma PMPs led directly to the decrease in 
NO synthase activity and increase in ROS production in GEnCs. Therefore, we further 
investigated the effect of PMPs on GEnCs by using purified PMPs derived from 
activated platelets stimulated by agonists in vitro. Consistently, PMPs released from 
activated platelets effectively inhibited NO synthase activity and SOD production, but 
increased ROS production, in GEnCs. In addition, PMPs reduced expression of the 
glycocalyx-associated core proteins glypican-1 and syndecan-1, suggesting a disruption 
of GEnC structural integrity. The permeability assay confirmed that PMPs reduced 
permeability of the glomerular endothelial cell barrier, as shown by increased FITC-
BSA passage through GEnCs. These alterations of GEnCs induced by PMPs are 
consistent with the manifestations of glomerular endothelium injury in DN. To confirm 
these findings from the in vitro study, we treated diabetic rats with aspirin, which 
effectively reduced the level of PMPs from week 8. Consistently, our in vivo study 
revealed that inhibition of PMPs protected against GEnC injury in early DN, favouring 
the restoration of GEnC fenestration, improvement of the glycocalyx and tight junctions, 
and increased NO synthesis and SOD activity. A previous clinical study reported that 
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the circulating PMP level was associated with micro- and macro-angiopathy in young 
patients with type 1 diabetes. 23 Here, we first demonstrated that PMPs contributed to 
the progression of early DN by directly inducing glomerular endothelial damage. It 
suggests that PMPs could be a therapeutic target for the treatment of early DN. Tarnow 
et al. found that nephropathy in type 1 diabetes was associated with increased 
circulating activated platelets and platelet hyperreactivity37. Some clinical and 
experimental studies reported that aspirin provided a renoprotective role in DN, which 
was mainly through reducing urinary protein, decreasing the expression of 
inflammatory factors and collagen in kidneys38, 39. However, clinical application of 
aspirin in DN treatment is still relatively insufficient and its mechanism for DN 
improvement is not very clear. Our findings evoked a novel therapeutic concept for DN, 
implying that the pharmacological inhibition of PMPs released from activated platelets 
might prevent glomerular endothelial injury. Thus, besides traditional pharmacological 
efficacies, aspirin could be exploited as a drug for the prevention of glomerular 
endothelial injury in the progression of early DN.   
Next, we explored potential mechanisms of glomerular endothelial injury induced by 
PMPs. It has been reported that PMPs regulate the signalling pathway in target cells 
both at the gene and protein levels depending on its contents. Ceroi et al 40 demonstrated 
that PMPs stimulated liver X receptor activation in plasmacytoid dendritic cells. 
Laffont et al 34 showed that PMPs regulated the gene expression of F-box/WD repeat-
containing protein 7 and ephrin A1 in human umbilical vein endothelial cells. 
Increasing evidence has indicated that mTORC1 plays a crucial role in the regulation 
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of kidney cell homeostasis and has been implicated in the development of glomerular 
lesions in DN.41 The activation of mTORC1 induces oxidative stress, apoptosis, and 
phenotypic changes in podocytes.42, 43 In addition, downregulation of the mTORC1 
pathway alleviates hindlimb ischaemic injury in diabetic mice by improving the 
vascular structure as well as attenuating the inflammation, oxidative stress, and 
apoptosis in endothelial cells.44 Our previous studies indicated that mTORC1 activation 
induced by inflammation contributed to atherosclerosis through disruption of the low-
density lipoprotein receptor pathway in vascular smooth muscle cells.45 In the present 
study, we demonstrated that PMPs activated the mTORC1 pathway by increasing the 
phosphorylation levels of mTOR and their downstream proteins S6K1 and 4EBP1 in 
GEnCs in vitro. In contrast, inhibition of PMPs by aspirin decreased activation of the 
mTORC1 pathway in GEnCs of diabetic rats. Disruption of mTORC1 signalling by the 
knockdown of raptor or rapamycin protected against the PMP-induced decrease in NO 
synthases, SOD and eNOS activity, increase of ROS production, loss of glycocalyx and 
tight junctions, and hyperpermeability in GEnCs. Consistent with these in vitro results, 
rapamycin improved the above alterations of GEnCs in early DN, although the PMP 
level in kidney was not changed. Thus, the mTORC1 pathway modulated PMP-induced 
GEnC injury. 
It is known that PMPs are the basic storage units for different active proteins in platelets, 
including resting platelet membrane proteins and a variety of active substances. 
Previous studies have verified the capacity of PMPs to elicit or disseminate a range of 
cytokines and chemokines, transcription factors, and microRNAs to recipient cells.34, 46 
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For example, Michael et al 47 showed that PMPs infiltrated solid tumours and 
transferred platelet RNA to tumour cells in vivo and in vitro. Using a protein microarray 
technique, we found that activated platelets released the vast majority of inflammatory 
cytokines in PMPs. CXCL7 was richly expressed and significantly increased in PMPs 
released by activated platelets. CXCL7 is one kind of cytokine in the CXCL family that 
signal through the G-protein-coupled receptors CXCR1 and CXCR2, which leads to 
activation of intracellular signalling pathways.48 In this study, we found that the 
expression of CXCR1 and 2 in GEnCs significantly increased following treatment with 
PMPs, suggesting that PMP-derived CXCL7 interacted with GEnCs by binding to 
CXCR1 and 2. Interestingly, CXCL7 activated the mTORC1 pathway in GEnCs in a 
dose-dependent manner, which was inhibited by CXCL7 blockade using CXCL7 
neutralizing antibody or an inhibitor of CXCL7 receptors, SB225002. These findings 
suggest that CXCL7 is a major PMP-derived regulator of glomerular endothelial injury.  
In summary, increased PMPs contributed to glomerular endothelial injury in early DN 
through the CXCL7 released from PMPs. The potential underlying mechanism was 
correlated with activation of the mTORC1 pathway in glomerular endothelial cells 
induced by CXCL7. Persistent PMP release finally resulted in functional and structural 
damage to the glomerular endothelium, an increase in permeability, urinary albumin 
leakage, and the progression of DN (Figure 9). Our findings herein may provide a 
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Figure legends 
Fig. 1．Inhibition of PMPs decreased albuminuria and ameliorated glomerular 
hypertrophy and mesangial matrix accumulation in early DN. Diabetes was 
induced by one intraperitoneal injection of STZ at 60 mg/kg body weight in 0.1 mol/l 
of sodium citrate buffer. Normal control rats were treated with vehicle (Ctrl) and 
diabetic rats were treated with vehicle (DM) or aspirin (15 mg/kg) (DM+Asp), and then 
killed at weeks 4, 8, and 12. (A-B) Plasma MPs were isolated according to a circulating 
MP isolation procedure and observed by electron microscopy (scale bar: 200nm and 
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500nm). (C) The plasma PMP level was analysed by flow cytometry. MPs from DM 
rats or annexin V buffer controls, isotype controls，and MPs after lysis were analysed 
by flow cytometry. PMPs were defined as CD61+/Annexin V+ events in Q2 window 
and analysed for quantification. (D) The results are expressed as events/ml of plasma 
(mean±SD, n=8). *P<0.05, **P<0.01 compared with Ctrl; #P<0.05 compared with DM 
group. (E-F) The presence of CD61+ PMPs (green dots) within the glomeruli in the 
renal cortexes of rats at week 12 was determined by immunofluorescent staining. Nuclei 
were stained with DAPI (blue). (scale bar: 20 µm). (G) Double immunofluorescent 
staining of CD61 (green) and CD63 (red) in glomeruli of DM rats at week 12.	Nuclei 
were stained with DAPI (blue). (scale bar: 20 µm). (H and I) Protein levels of CD61 in 
renal cortexes of rats at week 12 were detected by Western blotting. The relative density 
of protein bands were quantified and normalized to β-actin (mean±SD, n=5). *P<0.05, 
**P<0.01 compared with Ctrl; #P< 0.05 compared with DM group. Blood glucose 
levels (J), BUN (K), serum creatinine (L), the urinary albumin/creatinine ratio (M), and 
the ratio of kidney weight to body weight (N) in rats were measured (mean±SD, n=8). 
*P<0.05, **P<0.01 compared with Ctrl; #P<0.05 and ##P<0.01 compared with DM 
group. (O) Histopathological changes were evaluated by PAS staining. Original 
magnification, ×400 (scale bar: 50µm). (P-Q) The glomerular area and  mesangial 
expansion score were determined from histology sections. *P<0.05, **P<0.01 
compared with Ctrl; #P<0.05 and ##P<0.01 compared with DM group. (Q) Correlation 
analysis between the plasma PMP level and urinary albumin/creatinine ratio was 
determined by Spearman’s rank-order correlation analysis. 
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Fig. 2. PMPs induced glomerular endothelial injury in vitro. (A-B) Primary GEnCs 
were incubated with diabetic rat-derived PMPs labelled with PE-conjugated anti-CD61 
(red) antibody for 0, 2, 4, and 12 hours at 37°C. The GEnCs were labelled with Alexa 
488-conjugated anti-CD31 (green) antibody and nuclei were stained with DAPI (blue), 
and uptake of PMPs was observed by confocal microscopy (scale bars: 20 µm and 
10µm). (C-D). GEnCs were co-incubated with PMPs labelled by PE-CD61 and 
inhibitors for 4 hours, PMPs uptake was quantified compared with control. The results 
were expressed as mean number of PMPs per cell. Ctrl: control. Dyn: Dynasore (80 
µmol/l). Chlo: Chlorpromazine (10 µg/ml). Lat: Latrunculin A (5 µmol/l) .Cyto: 
Cytochalasin D (600 nmol/l). Noco: Nocodazole (20 µmol/l). (scale bars: 5µm). (E and 
F) Primary GEnCs were incubated without or with 0, 103/ml, 104/ml, 105/ml, and 106/ml 
of MPs derived from diabetic rats for 24 hours. The NO level in the culture supernatant 
(E) and intracellular ROS in GEnCs (F) were measured (mean±SD, n=4 experiments). 
*P<0.05 compared with control (Ctrl); **P<0.05 compared with DM-PMPs (103), 
***P<0.05 compared with DM-PMPs (104), ****P<0.05 compared with DM-PMPs 
(105). (G) PMPs were isolated from platelets stimulated without or with collagen (Col, 
25 µg/ml), high glucose (HG, 30 mmol/l), or collagen plus high glucose (Col+HG) and 
quantified by flow cytometry. The results are expressed as the mean fold changes vs 
unstimulated platelets, which were used as a reference (mean±SD, n=3 experiments). 
*P<0.05, **P<0.01 compared with Ctrl; #P<0.05 compared with Col-PMPs group. (H-
K) Primary GEnCs were incubated without or with 5×106 /ml of different types of PMPs 
for 24 hours. NO level (H) in culture supernatant, activity of eNOS (I) and SOD (J), 
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and intracellular ROS (K) were measured in GEnCs (mean±SD, n=3 experiments). 
*P<0.05, **P<0.01 compared with Ctrl; #P<0.05 compared with Col-PMPs group. (L) 
Expression of glypican-1 (green) and syndecan-1 (red) in GEnCs was determined by 
immunofluorescent staining. Nuclei were stained with DAPI (blue) (scale bars: 20 µm). 
(M) The permeability of GEnCs was assessed by measuring the ratio of FITC-labelled 
albumin in the bottom after 1 hour (mean±SD, n=4 experiments).*P< 0.05, **P<0.01 
compared with Ctrl; #P<0.05 compared with Col-PMPs group. 
Fig. 3. Inhibition of PMPs protected glomerular endothelium against injury in 
early DN. Diabetes was induced by one intraperitoneal injection of STZ at 60 mg/kg 
body weight in 0.1 mol/l of sodium citrate buffer. Normal control rats were treated with 
vehicle (Ctrl) and diabetic rats were treated with vehicle (DM) or aspirin (15 mg/kg) 
(DM+Asp), and then killed at weeks 4, 8, and 12. (A) Glomerular ESL was determined 
by staining with rhodamine-labelled WGA. A coat of glomerular endothelial 
glycocalyx lined the luminal surface of the endothelial cells. Original magnification, 
×400(scale bars: 20 µm); enlarged image magnification, ×800(scale bars: 5 µm).(B)	
Quantitation of WGA staining in the glomerulus. *P<0.05, **P<0.01 compared with 
Ctrl; #P<0.05, ##P<0.01 compared with DM.  (C and D) The expression of glypican-1 
(green) and syndecan-1 (red) in renal tissues of rats was determined by 
immunofluorescent staining. Original magnification, ×400 (scale bars: 20 µm). (E and 
F) Quantitation of immunofluorescent staining for glypican-1 and syndecan-1. *P<0.05, 
**P<0.01 compared with Ctrl; #P<0.05, ##P<0.01 compared with DM. (G-H) Protein 
levels of glypican-1, syndecan-1, ZO-1, occludin, and ET-1 in renal cortexes of rats 
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were detected by Western blotting. The relative density of the protein bands was 
quantified and normalized to β-actin (mean±SD, n=5). *P<0.05, **P<0.01 compared 
with Ctrl; #P<0.05, ##P<0.01 compared with DM. (I) The ultra-microstructure of the 
glomerular filtration barrier, including the endothelial fenestration, glomerular 
basement membrane, and podocyte foot processes, was analysed by transmission 
electron microscopy (scale bars: 0.5 µm).(J-K) The glomerular	endothelial fenestration 
and  glomerular basement membrane thickness were determined from ultra-
microstructure images. *P<0.05, **P<0.01 compared with Ctrl; #P<0.05, ##P<0.01 
compared with DM group. (L) NO level and (M) SOD activity in the renal cortex of 
rats were measured (mean±SD; n=5). *P<0.05, **P<0.01 compared with Ctrl; #P<0.05, 
##P<0.01 compared with DM group. 
Fig. 4. PMP activation of mTORC1 signalling in GEnCs. (A-F) Primary GEnCs 
were incubated without or with 5×106 /ml of different types of PMPs for 24 hours. (A-
C) mRNA level of mTOR, S6K1 and 4EBP1 in GEnCs was detected by real-time PCR. 
(D) Expression of p-S6K1 in GEnCs was detected by immunofluorescent staining. 
Original magnification, ×400. (Scale bars: 20 µm). (E-F) Protein levels of mTOR, p-
mTOR, S6K1, p-S6K1, 4EBP1 and p-4EBP1 in GEnCs were detected by Western 
blotting. The relative intensity of protein bands was quantified, and the ratio of 
phosphoprotein to total protein was expressed (mean±SD, n=3 experiments). *P<0.05, 
**P<0.01 compared with Ctrl. (G-I) Diabetes was induced by one intraperitoneal 
injection of STZ at 60 mg/kg body weight in 0.1 mol/l of sodium citrate buffer. Normal 
control rats were treated with vehicle (Ctrl) and diabetic rats were treated with vehicle 
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(DM) or aspirin (15 mg/kg) (DM+Asp) for 12 weeks. (G) Co-expression of p-S6K1 
and CD31 in renal tissues of rats was determined by immunofluorescent staining. 
Original magnification, ×400 (scale bars: 20 µm). (H-I) Protein levels of mTOR, p-
mTOR, S6K1, p-S6K1, 4EBP1 and p-4EBP1 in renal cortexes of rats were detected by 
Western blotting. The relative intensity of protein bands was quantified, and the ratio 
of phosphoprotein to total protein was expressed (mean±SD, n=5). *P<0.05, **P<0.01 
compared with Ctrl; #P<0.05, ##P<0.01 compared with DM group. 
Fig. 5. PMPs mediated glomerular endothelial injury through activation of the 
mTORC1 pathway in vitro. Primary GEnCs were incubated without (Ctrl) or with 
5×106 /ml of PMPs (PMPs), PMPs plus 10 ng/ml of rapamycin (PMPs+Rapa), or 
pretreated with raptor siRNA (PMPs+siRaptor) or negative control siRNA 
(PMPs+siCtrl) for 24 hours. (A-B) Protein levels of mTOR, p-mTOR, S6K1, p-S6K1, 
4EBP1 and p-4EBP1 in GEnCs were detected by Western blotting. The relative 
intensity of the protein bands was quantified, and the ratio of phosphoprotein to total 
protein was expressed (mean±SD, n=3 experiments). *P<0.05, **P<0.01 compared 
with Ctrl; #P<0.05, ##P<0.01 compared with PMPs group. The NO level (C), eNOS 
activity (D), and intracellular ROS (E) in GEnCs were measured (mean±SD, n=3 
experiments). *P<0.05, **P<0.01 compared with Ctrl; #P<0.05, ##P<0.01 compared 
with PMPs group. (F) The expression of glypican-1 (green) and syndecan-1 (red) in 
GEnCs was determined by immunofluorescent staining. Nuclei were stained with DAPI 
(blue). Original magnification, ×400 (scale bars: 20 µm). (G-H) Protein levels of 
glypican-1, syndecan-1, ZO-1, occludin, and ET-1 in renal cortexes of rats were 
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detected by Western blotting. The relative intensity of the protein bands was quantified 
and normalized to β-actin (mean±SD, n=3 experiments). *P< 0.05, **P<0.01 compared 
with Ctrl; #P<0.05, ##P<0.01 compared with PMPs group. (I) The permeability of 
GEnCs was assessed by measuring the ratio of FITC-labelled albumin in the bottom 
after 1 hour (mean±SD, n=4 experiments). *P< 0.05, **P< 0.01 compared with Ctrl; 
#P< 0.05, ##P<0.01 compared with PMPs group. 
Fig. 6. PMPs mediated glomerular endothelial injury through activation of the 
mTORC1 pathway in vivo. Diabetes was induced by one intraperitoneal injection of 
STZ at 60 mg/kg body weight in 0.1 mol/l of sodium citrate buffer. Normal control rats 
were treated with vehicle (Ctrl) and diabetic rats were treated with vehicle (DM) or 
rapamycin (1 mg/kg) (DM+Rapa), and then killed at week 12. (A-B) The presence of 
CD61+ PMPs (green dots) within the glomerulus in the renal cortexes of rats was 
detected by immunofluorescent staining followed by fluorescence semi-quantitative 
analysis. Nuclei were stained with DAPI (blue) (scale bar: 20 µm).	(mean±SD, n=5). 
*P<0.05, **P<0.01 compared with Ctrl. (C-D) The ultra-microstructure of endothelial 
fenestration was observed by electron microscopy and the	 endothelial fenestrations 
were quantified. (scale bars: 0.5 µm). *P<0.05, **P<0.01 compared with Ctrl; #P<0.05 
compared with DM. (E) Glomerular ESL was determined by staining with rhodamine-
labelled WGA. A coat of glomerular endothelial glycocalyx lined the luminal surface 
of endothelial cells. Original magnification, ×400(scale bars: 20 µm); enlarged image 
magnification, ×800(scale bars: 5 µm). (F) Expression of glypican-1 (green) and 
syndecan-1 (red) in renal tissues of rats was determined by immunofluorescent staining. 
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Original magnification, ×400 (scale bars: 20 µm). Nuclei were stained with DAPI (blue). 
(G and H) Protein levels of glypican-1, syndecan-1, ZO-1, occludin, and ET-1 in renal 
cortexes of rats were detected by Western blotting. The relative intensity of the protein 
bands was quantified and normalized to β-actin (mean±SD, n=5). *P<0.05, **P<0.01 
compared with Ctrl; #P<0.05, ##P<0.01 compared with DM. (I) NO levels and SOD 
activity (J) in renal cortexes of rats were measured (mean±SD, n=5). *P<0.05, 
**P<0.01 compared with Ctrl; #P<0.05, ##P<0.01 compared with DM. 
Fig. 7. PMP-derived CXCL7 contributed to GEnC injury. (A) Concentrations of 
CXCL7 in different types of PMPs lysate were measured by ELISA (mean±SD, n=4 
experiments). *P<0.05, **P<0.01 compared with Ctrl. (B) Primary GEnCs were 
incubated with Ctrl or Col+HG-PMPs for 24 hours. The mRNA levels of the CXCR1 
and CXCR2 in GEnCs were determined by real-time PCR (mean±SD, n=3 
experiments). *P<0.05, **P<0.01 compared with Ctrl. (C-D) GEnCs were treated with 
CXCL7 (1, 10, 20, 40 or 100 ng/ml) for 24 hours. Protein levels of mTOR, p-mTOR, 
S6K1, p-S6K1, 4EBP1 and p-4EBP1 in GEnCs were detected by Western blotting. The 
relative intensity of the protein bands was quantified, and the ratio of phosphoprotein 
to total protein was expressed (mean±SD, n=3 experiments). *P<0.05, **P<0.01 
compared with Ctrl.(E-O) GEnCs were pretreated without or with SB225002 (1 mmol/l) 
for 2 hours and then incubated with 5×106/ml PMPs for 24 hours. (E-F) Protein levels 
of mTOR, p-mTOR, S6K1, p-S6K1, 4EBP1 and p-4EBP1 in GEnCs were detected by 
Western blotting. The relative intensity of the protein bands was quantified, and the 
ratio of phosphoprotein to total protein was expressed (mean±SD, n=3 experiments). 
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*P<0.05, **P<0.01 compared with Ctrl; #P< 0.05, ##P<0.01 compared with PMPs. NO 
level (G), eNOS (H) and SOD (I) activity, and and intracellular ROS (J) in GEnCs were 
measured (mean±SD, n=4 experiments). *P<0.05, **P<0.01 compared with Ctrl; 
#P<0.05, ##P<0.01 compared with PMPs. (K) The GEnC glycocalyx was evaluated by 
WGA staining. (scale bars: 20 µm) (L) Expression of glypican-1 (green) and syndecan-
1 (red) in GEnCs was determined by immunofluorescent staining. Nuclei were stained 
with DAPI (blue). Original magnification, ×400 (scale bars: 20 µm). (M-N) Protein 
levels of glypican-1, syndecan-1, ZO-1, occludin, and ET-1 in renal cortexes of rats 
were detected by Western blotting. The relative intensity of the protein bands was 
quantified and normalized to β-actin (mean±SD, n=3 experiments). *P<0.05, **P<0.01 
compared with Ctrl; #P<0.05, ##P<0.01 compared with PMPs. (O) Permeability of 
GEnCs was assessed by measuring the ratio of FITC-labelled albumin in the bottom 
after one hour (mean±SD, n=4 experiments). *P<0.05, **P<0.01 compared with Ctrl; 
#P<0.05, ##P <0.01 compared with PMPs. 
Fig. 8. CXCL7 neutralizing antibody blocked PMP-derived CXCL7 induced 
GEnC injury.	GEnCs were treated with 5×106/ml PMPs for 24 hours and anti-rat 
CXCL7 antibodies(1 µg/ml) for 24 hours. (A-B) Protein levels of mTOR, p-mTOR, 
S6K1, p-S6K1, 4EBP1 and p-4EBP1 in GEnCs were detected by Western blotting. The 
relative intensity of the protein bands was quantified, and the ratio of phosphoprotein 
to total protein was expressed (mean±SD, n=3 experiments). *P<0.05, **P<0.01 
compared with Ctrl; #P< 0.05, ##P<0.01 compared with PMPs. NO level (C), eNOS 
(D) and SOD (E) activity in GEnCs were measured (mean±SD, n=4 experiments). 
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*P<0.05, **P<0.01 compared with Ctrl; #P<0.05, ##P<0.01 compared with PMPs. (F) 
The GEnC glycocalyx was evaluated by immunofluorescent staining of glypican-1 
(green) and syndecan-1 (red) and WGA staining. Nuclei were stained with DAPI (blue). 
Original magnification, ×400 (scale bars: 10 µm). 
Fig. 9 Schematic diagram showing the role and mechanism of PMPs in glomerular 
endothelial injury in early diabetic nephropathy (DN). (A). In early DN, circulating 
PMPs released from activated platelets under hyperglycaemia conditions infiltrated the 
glomerulus and bound to the glomerular endothelium, thereby promoting glomerular 
endothelial injury and albumin leakage.(B) PMP-derived CXCL7 induced a reduction 
of the NO levels and eNOS and SOD activities, production of ROS in GEnCs, and 
destruction of GEnC glycocalyx and cell junctions, and hyperpermeability in GEnCs 
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